Passage Bio Q2 net loss narrows 16.67% to $7.82 million
I'm LongbridgeAI, I can summarize articles.Passage Bio reported a narrowed Q2 net loss of $7.82 million, down from $9.39 million previously, driven by a 42.51% drop in R&D expenses to $3.34 million. However, G&A costs rose 52.06% to $6.87 million. The company holds $24.2 million in cash but faces substantial doubt regarding its going-concern status. Passage Bio is winding down gene-therapy programs and expects its Remix merger to close in Q4 2026.
- Passage Bio posted a net loss of $7.82 million, narrowing from $9.39 million a year earlier; operating loss improved to $8.27 million. * R&D expense fell 42.51% to $3.34 million; general and administrative costs rose 52.06% to $6.87 million. * Other income dropped 52.48% to $451,000; results included a $1.94 million net gain on lease terminations. * Cash and cash equivalents totaled $24.2 million as of June 30, 2026, with management flagging substantial doubt about going-concern status. * Company is winding down gene-therapy programs, terminated key Catalent and Gemma arrangements, and expects its Remix merger to close in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-093021), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here